Soo-Ryum Yang
Overview
Explore the profile of Soo-Ryum Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Febres-Aldana C, Vojnic M, Odintsov I, Zhang T, Cheng R, Beach C, et al.
Cancer Discov
. 2025 Feb;
PMID: 39965191
MET fusions (MET-Fs) are oncogenic drivers that remain poorly characterized. Analysis of 56 MET-F-positive tumors from an institutional cohort of 91,119 patients (79,864 DNA-seq plus 11,255 RNA-seq) uncovered two forms...
2.
Zhao Y, Andoh T, Charles F, Reddy P, Paul K, Goar H, et al.
bioRxiv
. 2025 Jan;
PMID: 39803490
VISTA is a key immune checkpoint receptor under investigation for cancer immunotherapy; however, its signaling mechanisms remain unclear. Here we identify a conserved four amino acid (NPGF) intracellular motif in...
3.
Cooper A, Arfe A, Ricciuti B, Gagne A, Sholl L, Di Federico A, et al.
JTO Clin Res Rep
. 2025 Jan;
6(1):100759.
PMID: 39802817
Introduction: Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) are a recently defined group of aggressive cancers in which the effectiveness of standard treatments for lung cancer is unknown. Methods: We collected clinical,...
4.
Fanaroff R, Yang S, Tan K, Adusumilli P, Bodd F, Bowman A, et al.
Mod Pathol
. 2025 Jan;
38(5):100706.
PMID: 39788204
Histologic features, including architectural patterns, cytologic features, and 2021 World Health Organization nuclear grade have been shown to have prognostic significance in epithelioid diffuse pleural mesothelioma (DPM). Biphasic and sarcomatoid...
5.
Kim D, Vanderbilt C, Yang S, Nandakumar S, Nafa K, Feratovic R, et al.
Nat Commun
. 2025 Jan;
16(1):116.
PMID: 39747849
Comprehensive molecular profiling by next-generation sequencing has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally invasive procedures....
6.
Rekhtman N, Tischfield S, Febres-Aldana C, Lee J, Chang J, Herzberg B, et al.
Cancer Discov
. 2024 Aug;
15(1):83-104.
PMID: 39185963
Small cell lung carcinoma (SCLC) is a highly aggressive malignancy that is typically associated with tobacco exposure and inactivation of RB1 and TP53 genes. Here, we performed detailed clinicopathologic, genomic,...
7.
Liu S, Erazo T, Jee J, Arfe A, Gupta A, Pike L, et al.
Eur J Cancer
. 2024 Aug;
210:114257.
PMID: 39151324
Introduction: No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting....
8.
Kim D, Vanderbilt C, Yang S, Nandakumar S, Nafa K, Feratovic R, et al.
Res Sq
. 2024 Aug;
PMID: 39108489
Comprehensive molecular profiling by next generation sequencing (NGS) has revolutionized tumor classification and biomarker evaluation. However, routine implementation is challenged by the scant nature of diagnostic material obtained through minimally...
9.
Chen M, Yang S, Tao J, Desilets A, Diamond E, Wilhelm C, et al.
Clin Cancer Res
. 2024 Jun;
30(17):3812-3823.
PMID: 38922339
Purpose: Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course. Experimental Design: We collected data...
10.
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, et al.
Br J Cancer
. 2024 Jun;
131(3):601-610.
PMID: 38902532
Background: While NTRK fusion-positive cancers can be exquisitely sensitive to first-generation TRK inhibitors, resistance inevitably occurs, mediated in many cases by acquired NTRK mutations. Next-generation inhibitors (e.g., selitrectinib, repotrectinib) maintain...